A group of individuals from the University of Kentucky (UK) is part of a new team dedicated to substance use disorder research at the university. These researchers combined their years of expertise to ensure UK takes a holistic approach when addressing substance use disorder in the Commonwealth. Recently, select members of this team have been invited to present at the National Rx Drug Abuse and Heroin Summit in Atlanta, GA and will be presenting their findings later this month.
New findings from the University of Kentucky published in the Journal of Neuroscience demonstrate that there may be ways to address blood-brain barrier dysfunction in epilepsy.
The UK College of Pharmacy Research Publication Highlight for November of 2017 was published in Alcohol and is titled “Increased expression of M1 and M2 phenotypic markers in isolated microglia after four-day binge alcohol exposure in male rats” The project was led by Dr. Hui Peng, an Assistant Professor of Pharmaceutical Sciences in the laboratory of Dr. Kimberly Nixon, Associate Professor of Pharmaceutical Sciences. Graduate students Chelsea Geil and Kevin Chen as well as postdoctoral fellow, Justin McClain, each in the Nixon laboratory contributed to the project.
New findings from University of Kentucky faculty published in Scientific Reportsreveals a novel cell signaling interaction that may prevent a key step in cancer progression. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky College of Pharmacy is committed to reducing these numbers.
The UK College of Pharmacy Research Publication Highlight for October of 2017 was published in Pharmaceutical Research and is titled “Development of Halofluorochromic Polymer Nanoassemblies for the Potential Detection of Liver Metastatic Colorectal Cancer Tumors Using Experimental and Computational Approaches.”
This summer, University of Kentucky’s Igniting Research Collaborations (IRC) awarded almost $300,000 in pilot grants to support cross-college interdisciplinary research and scholarship. This collaborative approach to science further enables research focused on health conditions prominent in the Commonwealth and beyond.
Approximately $5 million in additional funding from the Global Health Innovative Technology Fund (GHIT) has been awarded to the lab of Dean Kip Guy at the University of Kentucky College of Pharmacy, in partnership with Eisai Pharmaceuticals and Medicines for Malaria Venture (MMV), for ongoing malaria research.
The UK College of Pharmacy will host its eighth annual Symposium on Drug Discovery and Development on Thursday, August 10, 2017. This year’s Symposium is in partnership with the College’s Natural Products Consortium. The Symposium will feature recent advances in the design of antibody-drug conjugates for treating cancer and other diseases, as well as advances in our understanding how Nature generates compounds that have been exploited in medicine, agriculture, and biotechnology.
New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky College of Pharmacy is committed to reducing these numbers.
The UK College of Pharmacy Research Publication Highlight for April 2017 was published in Immunobiology and is titled, “Pneumocystis infection alters the activation state of pulmonary macrophages”.
